IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Days Sales Outstanding : 121.60 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Days Sales Outstanding?

IPI Legacy Liquidation Co's average Accounts Receivable for the three months ended in Sep. 2023 was $6.69 Mil. IPI Legacy Liquidation Co's Revenue for the three months ended in Sep. 2023 was $5.02 Mil. Hence, IPI Legacy Liquidation Co's Days Sales Outstanding for the three months ended in Sep. 2023 was 121.60.

The historical rank and industry rank for IPI Legacy Liquidation Co's Days Sales Outstanding or its related term are showing as below:

IMPLQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 115.62 Med: 432.81 Max: 738.74
Current: 115.62

During the past 4 years, IPI Legacy Liquidation Co's highest Days Sales Outstanding was 738.74. The lowest was 115.62. And the median was 432.81.

IMPLQ's Days Sales Outstanding is ranked worse than
71.51% of 895 companies
in the Biotechnology industry
Industry Median: 72.67 vs IMPLQ: 115.62

IPI Legacy Liquidation Co's Days Sales Outstanding declined from Sep. 2022 (161.70) to Sep. 2023 (121.60).

IPI Legacy Liquidation Co Days Sales Outstanding Historical Data

The historical data trend for IPI Legacy Liquidation Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Days Sales Outstanding Chart

IPI Legacy Liquidation Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

738.74

126.88

IPI Legacy Liquidation Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Sales Outstanding	Get a 7-Day Free Trial											161.70	123.66	143.22	90.65	121.60

Competitive Comparison of IPI Legacy Liquidation Co's Days Sales Outstanding

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IPI Legacy Liquidation Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Days Sales Outstanding falls into.

IPI Legacy Liquidation Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

IPI Legacy Liquidation Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (1.352	+	7.444)	/	2 )	/	12.652	*	365
=	4.398					/	12.652	*	365
=	126.88

IPI Legacy Liquidation Co's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding (Q: Sep. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )	*	Days in Period
=	( (6.801	+	6.586)	/	2 )	/	5.023	*	365 / 4
=	6.6935					/	5.023	*	365 / 4
=	121.60

IPI Legacy Liquidation Co (OTCPK:IMPLQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

IPI Legacy Liquidation Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Executives

Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb	officer: CFO	24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin	officer: VP, Controller & Interim CFO	C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson	director	1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams	director, officer: COB, CEO and President	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp	10 percent owner	525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019